Insider Selling: Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Sells 11,136 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) Director Jeffrey S. Flier sold 11,136 shares of the firm's stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $40.02, for a total value of $445,662.72. Following the transaction, the director owned 24,070 shares in the company, valued at approximately $963,281.40. This trade represents a 31.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scholar Rock Stock Performance

Shares of NASDAQ:SRRK traded down $2.14 during midday trading on Friday, hitting $40.72. The company's stock had a trading volume of 1,896,457 shares, compared to its average volume of 1,316,526. The stock has a market capitalization of $3.87 billion, a price-to-earnings ratio of -16.09 and a beta of 0.33. The stock's 50 day simple moving average is $33.56 and its 200 day simple moving average is $35.13. Scholar Rock Holding Corporation has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.25 and a current ratio of 10.25.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.04). During the same quarter in the prior year, the business earned ($0.59) earnings per share. As a group, research analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Institutional Investors Weigh In On Scholar Rock

Several hedge funds and other institutional investors have recently made changes to their positions in SRRK. Victory Capital Management Inc. acquired a new stake in shares of Scholar Rock in the fourth quarter valued at about $374,000. Raymond James Financial Inc. acquired a new stake in shares of Scholar Rock in the fourth quarter valued at about $2,625,000. Swiss National Bank grew its position in Scholar Rock by 37.1% during the fourth quarter. Swiss National Bank now owns 115,400 shares of the company's stock worth $4,988,000 after buying an additional 31,200 shares in the last quarter. Corient Private Wealth LLC acquired a new stake in Scholar Rock during the fourth quarter worth about $394,000. Finally, Cibc World Markets Corp acquired a new stake in Scholar Rock during the fourth quarter worth about $314,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on SRRK shares. Cantor Fitzgerald started coverage on Scholar Rock in a report on Thursday. They set an "overweight" rating on the stock. Wedbush restated an "outperform" rating and set a $50.00 target price on shares of Scholar Rock in a report on Wednesday, June 18th. Finally, Lifesci Capital upgraded Scholar Rock to a "strong-buy" rating in a report on Tuesday, June 3rd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.